<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890175</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-004-105</org_study_id>
    <secondary_id>10 April 2009</secondary_id>
    <nct_id>NCT00890175</nct_id>
  </id_info>
  <brief_title>Staccato Loxapine Pulmonary Safety in Patients With Asthma</brief_title>
  <official_title>Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety of 2 inhaled doses of Staccato Loxapine
      within a day in patients with asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FEV1 from baseline by spirometry</measure>
    <time_frame>at each post-treatment time point (15 min to 34 hr)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in FVC from baseline by spirometry</measure>
    <time_frame>at each post-treatment time point (15 min to 34 hr)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events</measure>
    <time_frame>Post-treatment time points</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Inhaled loxapine @ 0 &amp; 10 h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation of 10 mg of loxapine at 0 and 10 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled placebo @ 2 &amp; 10 hours</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhalation of 0 mg of loxapine (placebo) at 0 and 10 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled loxapine @ 0 &amp; 10 h</intervention_name>
    <description>10 mg, 2 doses, 10 hours apart</description>
    <arm_group_label>Inhaled loxapine @ 0 &amp; 10 h</arm_group_label>
    <other_name>ADASUVE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled placebo @ 2 &amp; 10 hours</intervention_name>
    <description>placebo, 2 doses, 10 hours apart</description>
    <arm_group_label>Inhaled placebo @ 2 &amp; 10 hours</arm_group_label>
    <other_name>ADASUVE PLACEBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of mild to moderate persistent asthma for at least 6 months with
             pre-bronchodilator FEV1 ≥60% of predicted value.

        Exclusion Criteria:

          -  History of COPD, or any other acute or chronic pulmonary disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mildred D. Gottwald, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Alexza Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy and Asthma Medical Group &amp; Research Center, A.P.C.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gross N, Greos LS, Meltzer EO, Spangenthal S, Fishman RS, Spyker DA, Cassella JV. Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials. J Aerosol Med Pulm Drug Deliv. 2014 Dec;27(6):478-87. doi: 10.1089/jamp.2013.1114.</citation>
    <PMID>24745666</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma, Staccato loxapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loxapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

